Latest Headlines

31. Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio And Boltz To Accelerate Novel SLC Small-Molecule Discovery 6/22/2026

    Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.

32. Pheno Therapeutics Granted FDA IND Clearance For Lead Multiple Sclerosis Therapeutic Candidate PTD802 6/22/2026

    Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the  Investigational New Drug (IND) application for PTD802, the Company’s lead therapeutic candidate.

33. New European Initiative To Accelerate Drug Discovery For Cardiometabolic Diseases 6/19/2026

    The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).

34. Gandeeva And Zymeworks Use Cryo-EM To Accelerate Antibody Drug Discovery 6/18/2026

    Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc., a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.

35. SK Life Science, Inc. Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension 6/18/2026

    SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of focal seizures in adults.

36. Optimi Health Launches Standardized Microdose Psilocybin Products For Clinical Research 6/16/2026

    Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

37. Protillion Biosciences Announces Drug Discovery Collaboration With Merck 6/16/2026

    Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada.

38. IDBS And Alchemi Partner To Accelerate Biopharma Regulatory Filings With Compliant AI Agents 6/16/2026

    IDBS, a Danaher company and leading provider of cloud software for biopharma, and Alchemi, a leading applied AI company serving the world's largest pharma and biotech development teams, today announced a partnership connecting AI agents to data captured and contextualized in the IDBS Polar platform across the drug development lifecycle.

39. Clinical Trials On Alzheimer's Disease Conference And Alzheimer's Drug Discovery Foundation Partner To Advance Emerging Biotech Innovation At CTAD 2026 6/16/2026

    The Clinical Trials on Alzheimer's Disease (CTAD) conference and the Alzheimer's Drug Discovery Foundation (ADDF) today announced they will collaborate on CTAD's annual Biotech Showcase, bringing together CTAD's expertise in clinical trials with the ADDF's unique ability to convene scientists, investors, pharmaceutical leaders, and philanthropists. The initiative is designed to spotlight promising biotechnology companies developing next-generation therapeutics, diagnostics, and technologies for Alzheimer's and related dementias.

40. Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence In Translational Research And Drug Discovery 6/15/2026

    Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use.